GLP-1受容体作動薬と乳がんリスク低下の関連を示唆する研究結果

2026年06月06日(土)

AIによるレポート

大規模な観察研究により、オゼンピックやウゴービといったGLP-1受容体作動薬を服用している女性では、乳がんの発症リスクが約30パーセント低いことが示された。

研究チームは、2022年1月から2025年6月にかけてペンシルベニア大学医学部（Penn Medicine）で乳がん検診を受けた、BMI 25以上の45歳から80歳の女性11万1000人以上の電子カルテを調査した。その結果、GLP-1受容体作動薬を処方されていたグループでは、全体の分析で乳がん発症リスクが35.1パーセント低く、マッチング分析においても30.5パーセント低いことが判明した。この知見は、2026年米国臨床腫瘍学会（ASCO）年次総会で発表され、学術誌『JCO Oncology Practice』に掲載された。ペンシルベニア大学ペレルマン医学大学院の教授であるエリザベス・マクドナルド氏は、今回の研究は観察研究であり因果関係を証明するものではないと指摘した。マクドナルド氏らは今後、GLP-1受容体作動薬が高リスクの女性における乳がん予防に有効かどうかを検証するための臨床試験を開始する予定である。これらの薬剤はがん発症に関連する経路に影響を与えるが、体重減少も観察された有益性に寄与している可能性がある。

Realistic illustration contrasting social stigma: neutral for overweight, positive for exercise weight loss, negative for Ozempic users.

Study finds people who use Ozempic-like drugs for weight loss face added stigma

2026年05月05日(火) AIによるレポート AIによって生成された画像事実確認済み

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

Study links Ozempic to lower depression and anxiety risks

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

2026年05月21日(木) AIによるレポート事実確認済み

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

健康

Semaglutide shows strong weight loss results for adults over 65

健康

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

技術

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

Teddi Mellencamp sought weight-loss meds amid stage 4 cancer battle

Teddi Mellencamp, the Real Housewives of Beverly Hills alum, spilled on her podcast that she begged her doctor for GLP-1 weight-loss drugs while battling cancer. She gained weight from steroids but got shut down. Joking about the irony, she quipped about living her best life without the meds.

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

2026年04月01日(水) AIによるレポート

The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Researchers at Vanderbilt Health discovered that both popular weight loss drugs and bariatric surgery significantly reduce fat mass while causing modest losses in fat-free mass, including muscle, in patients with obesity. The findings, based on over 3,000 patients, show improvements in overall body composition over 24 months. Maintaining this balance is crucial for long-term health, the study emphasizes.

2026/06/05 14:44